Sanofi

Quiet times return for biopharma takeouts
Quiet times return for biopharma takeouts
EP Vantage
M&A
Alexion
Amgen
AstraZeneca
Biogen
Five Prime Therapeutics
Gilead Sciences
GW Pharma
Horizon Therapeutics
Immunomedics
Jazz Pharmaceutical
Kymab
Merck
Pandion
Sanofi
Viela Bio
Flag link:
5 takeaways from AACR, one of the year's top meetings on cancer drugs
5 takeaways from AACR, one of the year's top meetings on cancer drugs
BioPharma Dive
AACR
CAR-T
Merck
Roche
Sanofi
Synthorx
Eli Lilly
Bristol Myers Squibb
Flag link:
Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking
Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking
Fierce Pharma
reputation
pharma industry
Sanofi
Novo Nordisk
Roche
Eli Lilly
Bristol Myers Squibb
Flag link:
Sanofi teams with virtual reality biotech on oral Dupixent successor
Sanofi teams with virtual reality biotech on oral Dupixent successor
Endpoints
Sanofi
Dupixent
C4X Discovery
small molecule drugs
Flag link:
‘Innovative vaccines on a massive scale’: Sanofi to create $475m vaccine production site in Singapore
‘Innovative vaccines on a massive scale’: Sanofi to create $475m vaccine production site in Singapore
Biopharma Reporter
vaccines
Sanofi
Singapore
environmental concerns
drug manufacturing
carbon neutrality
Flag link:
Sanofi spends $160M in bet that Tidal’s tech gets it to off-the-shelf CAR-T therapy
Sanofi spends $160M in bet that Tidal’s tech gets it to off-the-shelf CAR-T therapy
MedCity News
Sanofi
M&A
Tidal Therapeutics
CAR-T
MRNA
Flag link:
Sanofi drops 'intriguing' data on rival to Bristol Myers' bempeg
Sanofi drops 'intriguing' data on rival to Bristol Myers' bempeg
Fierce Biotech
Sanofi
solid tumors
Bristol Myers Squibb
Nektar Therapeutics
Synthorx
clinical trials
Flag link:
Big pharma freshens up
Big pharma freshens up
EP Vantage
Merck
Bristol Myers Squibb
Astellas
Novo Nordisk
AbbVie
Sanofi
Flag link:
Sanofi forms nonprofit unit to provide essential medicines to some low-income countries
Sanofi forms nonprofit unit to provide essential medicines to some low-income countries
Marketwatch
Sanofi
non-profits
Flag link:
Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma
Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma
Endpoints
Sanofi
JNJ
Sarclisa
Kyprolis
Multiple Myeloma
Flag link:
Daiichi exits combo vaccine pact with Sanofi after pertussis shot manufacturing glitches
Daiichi exits combo vaccine pact with Sanofi after pertussis shot manufacturing glitches
Fierce Pharma
Daiichi Sankyo
Sanofi
vaccines
VN-0105
pertussis
drug manufacturing
Flag link:
Looking to prepare for the next flu pandemic, Sanofi drops $700M+ into new Toronto facility for Fluzone production
Looking to prepare for the next flu pandemic, Sanofi drops $700M+ into new Toronto facility for Fluzone production
Endpoints
Sanofi
Fluzone
Canada
Toronto
vaccines
drug manufacturing
Flag link:
5 FDA approval decisions to watch in the second quarter
5 FDA approval decisions to watch in the second quarter
BioPharma Dive
FDA
Biogen
aducanumab
Acadia Pharmaceuticals
pimavanserin
AstraZeneca
vaccines
COVID-19
Sanofi
Avalglucosidase alfa
Pfizer
pneumococcal disease
Flag link:
Amgen v Sanofi ruling: It is time to kiss goodbye to broad, functional patent claims for antibodies
Amgen v Sanofi ruling: It is time to kiss goodbye to broad, functional patent claims for antibodies
Biopharma Reporter
Amgen
Sanofi
patents
antibodies
intellectual property
Flag link:
After spurning Sanofi for diabetes disappointment, Zealand nets FDA approval in severe hypoglycemia
After spurning Sanofi for diabetes disappointment, Zealand nets FDA approval in severe hypoglycemia
Endpoints
Zealand Pharma
Zegalogue
hypogylcemia
diabetes
Sanofi
Flag link:
Big pharma’s key catalysts in the second quarter
Big pharma’s key catalysts in the second quarter
EP Vantage
Biogen
Alzheimer's disease
aducanumab
Sanofi
breast cancer
FDA
Flag link:
Fidia Farmaceutici acquires Sanofi’s anti-inflammatory drugs portfolio
Fidia Farmaceutici acquires Sanofi’s anti-inflammatory drugs portfolio
Pharmaceutical Business Review
Sanofi
Fidia Farmaceutici
M&A
anti-inflammatories
Flag link:
With all the buzz in gene therapy, Sanofi offloads two small molecule sickle cell programs from $11.6B buyout to Global Blood Therapeutics
With all the buzz in gene therapy, Sanofi offloads two small molecule sickle cell programs from $11.6B buyout to Global Blood Therapeutics
Endpoints
Sanofi
sickle cell disease
gene therapy
gene editing
Global Blood Therapeutics
Flag link:
GSK kick-starts phase 3 Medicago-partnered COVID vaccine test
GSK kick-starts phase 3 Medicago-partnered COVID vaccine test
Fierce Biotech
GSK
Sanofi
UK
Medicago
vaccines
COVID-19
Flag link:
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Pharma Times
Sanofi
Regeneron
Libtayo
cervical cancer
clinical trials
Flag link:

Pages